Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities
Summary
Azenta announced strategic investments to strengthen GENEWIZ’s gene synthesis capabilities. The company signed an exclusive licensing agreement with Elegen for cell-free DNA synthesis technology and acquired SynPlexity for pooled gene assembly technology. These moves expand high-throughput discovery workflows and support biologics discovery, synthetic biology, protein engineering, and AI-enabled drug discovery. Azenta expects the combined technologies to improve quality, speed, scalability, and regional production capacity for customers.
AskAI Classifications
Sectors
Life Sciences and Pharmaceutical
Life Sciences Management
Life Sciences Analytics
Functions
No functions detected
Linked Companies
Azenta Life Sciences
$500M to $1B